Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancerAlessandra Gennari, Stefano Iacobelli, Cinzia Orlandini et al.|Breast Cancer Research and Treatment|2008Cited by 12
A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)Michele De Tursi, Silvia Iacobelli, Consiglia Carella et al.|Journal of Clinical Oncology|2007Cited by 2